Efficacy and safety of everolimus (Certican) plus once-daily prolonged-release tacrolimus (Graceptor) combination therapy in living donor kidney transplantation: Open-label, multicenter, randomized controlled trial.
Not Applicable
Recruiting
- Conditions
- Kidney transplantation
- Registration Number
- JPRN-UMIN000011562
- Lead Sponsor
- Tokyo Women's Medical University, Dep. Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1. Inability or un willingness to sign a consent form. 2. Subject under 20 years old. 3.ABO blood incompatible kidney transplantation 4.Unable to outpatient treatment in study period 5.Pregnancy or possible to pregnant 6.Serious digestive disease 7.Active infectious disease 8. Cancer 9. Hypersensibility to sirolimus or everolimus 10. Investigator considered inappropriate as a subject of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method